Neurocrine Biosciences | NBIX - 营业费用



金融业
股票价格
USD
资产
USD 5.36B
现金及等价物
USD 332.4M
销售成本
USD 39.4M
流动资产
USD 1.64B
流动负债
USD 874.5M
债务
USD 406.2M
EBIT
USD 219.9M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 2.85
股本和储备
USD 3.69B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 18.46B
净收入
USD 144.4M
营业费用
USD 739.1M
营业利润
USD 219.9M
普通股股本
USD 100.55M
PE价格收益
22.1
税前利润
USD 246.8M
销售收入
USD 959M
销售和管理费用
USD 383.1M
股票
USD 104.2M
贸易债权人
USD 691.3M
应收帐款人
USD 887M


营业费用 更改 日
AbbVie USD 10.27B 1000K 2026-06
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 4.78B 1.12B 2026-03
Biogen USD 2.98B 1.02B 2026-06
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Cytokinetics USD 200.58M 4.46M 2026-03
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Exelixis USD 359.47M 3.28M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Pfizer USD 90.1B 77.19B 2026-03
Prothena USD 25.29M 1.94M 2026-03
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Repligen USD 183M 8.72M 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Teva Pharmaceutical Industries USD 3.92B 691M 2026-06
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03